Literature DB >> 28838382

Assessing the prognostic impact of the International Association for the Study of Lung Cancer proposed definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer surgery.

Matteo Gagliasso1, Giuseppe Migliaretti2, Francesco Ardissone3.   

Abstract

OBJECTIVE: The aim of this study was to assess the prognostic impact of the definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer (NSCLC) surgery, as proposed by the International Association for the Study of Lung Cancer (IASLC). PATIENTS AND METHODS: Single institution retrospective study of consecutive patients undergoing surgery for NSCLC between 1998 and 2007. Complete resection was defined by absence of gross and microscopic residual disease; systematic nodal dissection; no extracapsular extension in distal lymph nodes; and negativity of the highest mediastinal node removed. An uncertain resection was defined by free resection margins, but one of the following applied: lymph node evaluation less rigorous than systematic nodal dissection; positivity of the highest mediastinal node removed; presence of carcinoma in situ at the bronchial margin; positive pleural lavage cytology. A resection was defined incomplete by presence of residual disease; extracapsular extension in distal lymph nodes; positive cytology of pleural or pericardial effusions. Follow-up was complete and all patients were followed up until death or for a minimum period of 5 years. Overall survival (OS) was analyzed using Kaplan-Meier method, log rank test, and Cox proportional hazards model.
RESULTS: A total of 1277 patients were identified. One thousand and three patients (78.5%) underwent complete resection, 185 (14.5%) underwent uncertain resection, and 89 (7.0%) underwent incomplete resection. Both uncertain and incomplete resection were associated with significantly worse OS when compared with complete resection (hazard ratio: 1.69 and 3.18, respectively; both p=0.0001). Median OS and 5-year survival rate were 80.1, 39.9, 17.3 months and 58.8%, 37.3%, 15.7% in patients undergoing complete, uncertain, and incomplete resection, respectively.
CONCLUSION: The present analysis suggests that in patients undergoing surgery for NSCLC, the IASLC definitions of complete, uncertain, and incomplete resection are associated with statistically significant differences in survival.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Incomplete resection; Non-small cell lung cancer; Residual disease; Surgery; Survival

Mesh:

Year:  2017        PMID: 28838382     DOI: 10.1016/j.lungcan.2017.07.013

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  12 in total

Review 1.  Lymph node dissection during sublobar resection: why, when and how?

Authors:  Pascal-Alexandre Thomas
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

2.  Sleeve lobectomy and pneumonectomy: can they really be properly compared?

Authors:  Ramón Rami-Porta; Sergi Call
Journal:  Transl Lung Cancer Res       Date:  2020-06

3.  Development of a nomogram for preoperative prediction of lymph node metastasis in non-small cell lung cancer: a SEER-based study.

Authors:  Chufan Zhang; Qian Song; Lanlin Zhang; Xianghua Wu
Journal:  J Thorac Dis       Date:  2020-07       Impact factor: 2.895

4.  Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization.

Authors:  Raymond U Osarogiagbon; Nicholas R Faris; Walter Stevens; Carrie Fehnel; Cheryl Houston-Harris; Philip Ojeabulu; Olawale A Akinbobola; Yu-Shen Lee; Meredith A Ray; Matthew P Smeltzer
Journal:  J Thorac Oncol       Date:  2019-11-26       Impact factor: 15.609

5.  Comparative Effectiveness of a Lymph Node Collection Kit Versus Heightened Awareness on Lung Cancer Surgery Quality and Outcomes.

Authors:  Meredith A Ray; Carrie Fehnel; Olawale Akinbobola; Nicholas R Faris; Meghan Taylor; Alicia Pacheco; Matthew P Smeltzer; Raymond U Osarogiagbon
Journal:  J Thorac Oncol       Date:  2021-02-12       Impact factor: 15.609

6.  Spanish Lung Cancer Group SCAT trial: surgical audit to lymph node assessment based on IASLC recommendations.

Authors:  José Ramón Jarabo Sarceda; Sergio Bolufer Nadal; Roberto Mongil Poce; Pedro López de Castro; Ramón Moreno Balsalobre; Juan Carlos Peñalver Cuesta; Raul Embún Flor; Joaquín Pac Ferrer; Francisco Javier Algar Algar; Antonio Pablo Gámez García; Marcelo F Jiménez; Jesús Gabriel Sales-Badía; Eva Pereira; Bartomeu Massuti; Mariano Provencio; Florentino Hernando Trancho
Journal:  Transl Lung Cancer Res       Date:  2021-04

7.  [Correlation between Lymph Node Ratio and Clinicopathological Features and Prognosis of IIIa-N2 Non-small Cell Lung Cancer].

Authors:  Shanyuan Zhang; Liang Wang; Fangliang Lu; Yuquan Pei; Yue Yang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-11-20

8.  Glutathione Peroxidase 3 as a Biomarker of Recurrence after Lung Cancer Surgery.

Authors:  Bo Gun Kho; Ha-Young Park; Hyun-Joo Cho; Cheol Kyu Park; Young-Chul Kim; Ju-Sik Yun; Sang-Yun Song; Kook-Joo Na; Yoo-Duk Choi; Seung-Won Lee; In-Jae Oh
Journal:  J Clin Med       Date:  2020-11-24       Impact factor: 4.241

Review 9.  Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC).

Authors:  Li-Chung Chiu; Shu-Min Lin; Yu-Lun Lo; Scott Chih-Hsi Kuo; Cheng-Ta Yang; Ping-Chih Hsu
Journal:  Vaccines (Basel)       Date:  2021-06-23

10.  The Evolving Concept of Complete Resection in Lung Cancer Surgery.

Authors:  Ramón Rami-Porta
Journal:  Cancers (Basel)       Date:  2021-05-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.